Immunology

Food allergy treatment loses efficacy with time

(HealthDay)—Many children who are initially successfully treated for allergy to cow's milk by oral immunotherapy lose tolerance several years later, according to a letter to the editor published online June 27 in the Journal ...

Medications

Bristol-Myers, Sanofi revamp Plavix sales alliance (Update)

(AP)—Bristol-Myers Squibb Co. and France's Sanofi SA said Wednesday that they are restructuring their longtime partnership selling popular heart medications, now that their sales are plunging due to widespread competition ...

Medications

Bristol-Myers, Five Prime expand work on cancer, other drugs

Drugmaker Bristol-Myers Squibb Co. is expanding its collaboration with Five Prime Therapeutics Inc., which could receive more than $1.75 billion if they succeed in turning Five Prime's antibody-based drug candidates into ...

Diseases, Conditions, Syndromes

Low vitamin D levels common among spinal fusion patients

(HealthDay)—A substantially high number of patients undergoing spinal fusion have a vitamin D deficiency or inadequacy, according to a study published in the March 15 issue of Spine.

Medications

Elan enters $1B royalty deal with Theravance

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Other

Swiss pharma Novartis ups full-year sales outlook (Update)

Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Medications

Drugmaker Elan plans to explore sale of company (Update)

Shares of Elan Corp PLC jumped Friday after the Irish drugmaker said it will explore a possible sale of the company while its board continues to fend off a hostile takeover bid from Royalty Pharma.

page 1 from 2